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Aortic valve diseaseThe low-density lipoprotein-related receptor 5 and 6 (Lrp5 and
Lrp6) genes were cloned in 1998 based on their homology with the
low-density lipoprotein receptor (LDLR) [1e4]. Variants in either
LRP5 or LRP6 proteins have caused a number of disease processes in
the ﬁeld of bone [5,6], and have been associated with cardiovas-
cular disease [4,7e9]. In the study by Borrell-Pages et al. [10] in a
previous issue of Atherosclerosis, the authors conﬁrm the novel
ﬁnding that Lrp5 plays an atheroprotective role in the vascular
aorta. In thewildtype (WT) versus the Lrp5/mice there are larger
atheromatous lesions in the Lrp5/ mice as compared to WT lit-
termates, with an upregulation of the LDLR family members
including VLDR, Lrp6 and Lrp2. The mechanism postulated by the
authors implicates higher plasma cholesterol levels in the Lrp5/
mice as compared to theWT littermates as the driving factor for the
signiﬁcant increase in atheroma in the thoracic aortas. The pro-
duction of mice lacking Lrp5 revealed that Lrp5 deﬁciency led to
increased plasma cholesterol levels in mice fed a high-fat diet,
secondary to decreased hepatic clearance of chylomicron remnants
and also marked impaired glucose tolerance [7]. Lrp6 also regulates
bone, but has been found to have a low bone mass effect in patients
in which a putative partial loss-of-function mutation in Lrp6 was
identiﬁed to lead to early cardiovascular-related death associated
with increased plasma LDL, triglycerides, hypertension, diabetesDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.922.
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for the results in the novel study by Borell-Pages et al., implicating
the role of Lrp6, CLDR and Lrp2 in lipidmetabolism and progression
of aorta atherosclerosis [10].
Previous studies testing experimental hypercholesterolemia in
mouse and rabbit models demonstrated an upregulation of Lrp5
receptor expression and activation of cell proliferation and extra-
cellular matrix production critical in bone formation in the aortic
valve in vivo and ex vivo [8,9,12]. Speciﬁcity for the role of Lrp5 in
aortic valve calciﬁcation was tested in the previous study using a
high cholesterol diet in the Lrp5 null mice, which demonstrated
opposite results in the aortic valve: no evidence of atherosclerosis
or valve calciﬁcation [13].
The Lrp5 pathway also regulates bone formation in different
diseases of bone [5,14]. The discovery that the Lrp5 receptor carries
the gain of function [14] and loss of function [5] mutations in the
development of bone diseases, resulted in a number of studies
which have shown that activation of the canonical Wnt pathway is
important in osteoblastogenesis [7,15e17]. Three studies to date
have conﬁrmed the regulation of the Lrp5/Wnt pathway for car-
diovascular calciﬁcation in vivo and ex vivo [8,9,12]. In this pathway,
Wnt proteins bind to receptors composed of a frizzled protein and
either of the low-density lipoprotein receptor-related proteins Lrp5
or Lrp6. Signaling via Disheveled and/or Axin then results in inac-
tivation of a multiprotein complex including Axin, adenomatous
polyposis coli (APC), and glycogen synthase kinase-3ß that nor-
mally renders ß-catenin unstable. By inhibiting this complex, Wnt
signals lead to accumulation of ß-catenin in the cytosol and its
entry into the nucleus. Once in the nucleus, ß-catenin binds to
proteins of the T-cell factor/lymphoid enhancer factor-1 family and
modulates the expression of several target genes which include
Cyclin D, Cbfa1, and Sox9. Bone and cartilage are major tissues in
the vertebrate skeletal system, which is primarily composed of
three cell types: osteoblasts, chrondrocytes, and osteoclasts. In the
developing embryo, osteoblast and chrondrocytes both differen-
tiate from common mesenchymal progenitors in situ, where as
osteoclasts are of hematopoietic origin and brought in later by
invading blood vessels. Osteoblast differentiation and maturation
lead to bone formation controlled by two distinct mechanisms:
intramembranous and endochondral ossiﬁcation, both starting
from mesenchymal condensations.
The role of lipid signaling of the Lrp5 receptor has been
deﬁned in experimental in vitro and in vivo lipid models of
Fig. 1. Lrp5 is atheroprotective in the vascular aorta and osteogenic in the aortic valve
in the presence of experimental hypercholesterolemia.
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poproteins in vitro, is widely expressed in many tissues including
hepatocytes, adrenal gland and pancreas [4]. The production of
mice lacking Lrp5 revealed that Lrp5 deﬁciency led to increased
plasma cholesterol levels in mice fed a high-fat diet, secondary to
decreased hepatic clearance of chylomicron remnants, and also
marked impaired glucose tolerance [7]. The Lrp5 deﬁcient islets
also demonstrated a reduction of intracellular ATP and Calcium
in response to glucose, thereby decreasing glucose induced in-
sulin secretion [7]. Furthermore, experimental hypercholester-
olemia is associated with the increase in Lrp5 receptor
expression and activation of cell proliferation and extracellular
matrix production critical in bone formation [8]. These studies
provide evidence that lipoprotein metabolism is regulated by the
ﬁfth family member of the LDL co-receptor family Lrp5 in these
knockout mouse studies.
Embryonically, Wnt proteins bind to receptors composed of a
frizzled protein and either of the low-density lipoprotein receptor-
related proteins Lrp5 or Lrp6. In the developing embryo, osteoblast
and chrondrocytes, both differentiate from common mesenchymal
progenitors, and neural crest cells. The role of Wnt and Lrp5 cor-
eceptors in embryogenesis, have been the most detailed studies in
the ﬁeld to date [18]. Studies have demonstrated that the neural
crest cells are speciﬁc to the aortic valve [18] and mesodermal cells
are speciﬁc to the descending aorta [19]. Furthermore, a recent
study in the proximal ascending aorta where neural crest cells
reside, versus the descending aorta, indicate proximal aorta cal-
ciﬁes at an accelerated rate than the descending aorta in the
presence of hyperphosphatemia [20].
Fig. 1, demonstrates the role of hypercholesterolemia and the
role of the Lrp5 receptor in the aortic valve and the aorta. The
embryonic cell origin may provide another clue for why the
hypercholesterolemic Lrp5 null mouse develops excessive
atherosclerosis in the aorta that has mesodermal derived cells
[10], but does not develop calcifying valve lesion in the aortic
valve [13]. The novel ﬁnding by Borrell-Pages et al. [10], in this
issue of Atherosclerosis that Lrp5 plays an atheroprotective role
in the vascular aorta, is unique in the ﬁeld and will help to
further deﬁne the complex role of Lrp5 co-receptors in the ﬁeld
of embryogenesis, atherosclerosis, cell differentiation and bone
biology.
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